Publications

Journal Article Ppublish 9 citations
Electronic publication date
January 22, 2020

View on Pubmed.gov 31204552 | View on doi.org 10.1080/1083745...

Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer.

Search for publications in this journal Pharm Dev Technol - 24(9):1095-1103

Abstract

This study evaluated the delivery efficiency and antitumor effects of the intrapulmonary administration of antitumor small interfering ribonucleic acid (siRNA)-containing nanoparticles to mice with metastatic lung tumor. Fluorescence-labeled, siRNA-containing nanoparticles were administered using Liquid MicroSprayer to mice with metastatic lung tumors induced by the murine melanoma cell line B16F10. Fluorescent signals in the whole lung and in the tumor region following the intrapulmonary administration of siRNA-containing nanoparticles were stronger than those following intravenous administration. The intrapulmonary administration of nanoparticles containing a mixture of siRNA against MDM2, c-Myc, and vascular endothelial growth factor (VEGF) significantly improved survival and prolonged the survival of mice with metastatic lung tumor. In addition, after the intrapulmonary or intravenous administration of the mixture, the activity levels of interleukin-6 and -12, markers of systemic toxicity, were similar to those of nontreatment. These results indicate that the antitumor siRNA-containing nanoparticles were delivered efficiently and specifically to tumor cells, effectively silencing the oncogenes in the lung metastasis without any significant systemic toxicity.

References

No references provided.

Cited by 9 citations (total)

Journal Article Research Support, Non-U.S. Gov't Review

Inhaled RNA Therapy: From Promise to Reality.

Electronic publication date September 1, 2021

Search for publications in this journal Trends Pharmacol Sci

Michael Y T Chow [...] Jenny K W Lam et al.

RNA-based medicine is receiving growing attention for its diverse roles and potential therapeutic capacity. The largest obstacle in its clinical...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances